Pharmaceutical medicine

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, AstraZeneca, CMO, CD25, Biotechnology, Roche, Neoplasm, Physician, Obesity, Amgen, Icon, Pharmaceutical medicine, Bladder cancer, Royal college, ADC, Antibody, NHS, Safety, CB1, CSPC, Patient, CD137, Faculty, Partnership, Pharmaceutical industry

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points: 
  • NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
  • Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
  • “We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Retrieved on: 
Wednesday, February 14, 2024
Head, SAN, Senior, PD, Merck, Alzheimer's disease, Ionis Pharmaceuticals, GSK, MD, Cell potency, Pharmaceutical medicine, Neurological disorder, Assembly, Aspen, Howard University, Parkinson's disease, IPSC, Therapy, Pharmacology, Internal medicine, Organization, Patient, Pharmaceutical industry

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Key Points: 
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
  • "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer.
  • "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development.
  • Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery.

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024
DSM-IV codes, Employment, Erasmus MC, Pharmaceutical medicine, Drug development, Acquisition, FFPM, Disease, NDA, Astellas Pharma, Therapy, Pharmacovigilance, Faculty, GMC, General Medical Council, Acer, Growth, Patient, BioMarin Pharmaceutical, Compensated emancipation, Clinical research, Pharmaceutical industry

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.

Key Points: 
  • CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.
  • Dr. Quartel brings more than 20 years of experience in the international pharmaceutical industry with senior roles in clinical development, pharmacovigilance and medical affairs.
  • "It is an honor to welcome Dr. Quartel to our team during an exciting period of growth for Zevra after our recent acquisition of Acer Therapeutics and the expansion of our rare disease portfolio,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases.

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Tuesday, October 24, 2023
Drug development, Research, Bone marrow, Ovarian cancer, Nottingham Trent University, Medicine, Internal medicine, Bachelor, Biomedical sciences, George Washington School, Pediatric Hematology and Oncology, Medical Affairs Bureau, Pharmacy, European Society for Clinical Investigation, Pharmaceutical medicine, University of Zimbabwe, Postgraduate diploma, Epidermolysis bullosa, University, NDA, Cancer, Therapy, Patient, Myelodysplastic syndrome, Merrimack Pharmaceuticals, GSK plc, Medication, CMO, Nottingham, Johns Hopkins School of Medicine, King's College London, University of Surrey, IND, Consultant, Outline of health sciences, Patent, Rare, Inflammation, R, EB, Johnson & Johnson, Pharmaceutical industry, Nursing, Biotechnology, Science, Hematology, Honours degree

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Faculty, GSK, Royal college, University, Drug development, Senior, Tropical medicine, G protein-coupled receptor, Levick, University of Cambridge, Membership of the Royal College of Physicians of Ireland, Cancer, ETH Zurich, Faculty of Pharmaceutical Medicine, Multimedia, Biomarker, Computational chemistry, Doctor of Philosophy, Language, Paul Scherrer Institute, GPCR, Novartis, MD, Vivo, Drug discovery, Commonwealth Scholarship and Fellowship Plan, Artificial intelligence, Marie Cassidy, FRCPA, University of Newcastle, Pharmaceutical medicine, Pharmacology, Medical device, Pharmaceutical industry, EU, Physician, AI

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer

Retrieved on: 
Thursday, September 21, 2023
Faculty, Faron Pharmaceuticals, Drug development, AIM, CMO, Immunotherapy, Nasdaq First North, Limited, Medicine, Presidential Communications Group, Patient, Syndrome, Cancer, Rheumatology, Johnson & Johnson, Policy, Sanofi, Pharmaceutical medicine, Janssen Pharmaceuticals, Pharmaceutical industry, Management, Fine chemical, Nursing, Fårö, MD

TURKU, Finland and BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the appointment of Dr. Birge Berns, MD, as the Company’s interim Chief Medical Officer (CMO). Dr. Berns will be based in the UK and her appointment is effective starting September 22, 2023.

Key Points: 
  • TURKU, Finland and BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the appointment of Dr. Birge Berns, MD, as the Company’s interim Chief Medical Officer (CMO).
  • Dr. Berns will be based in the UK and her appointment is effective starting September 22, 2023.
  • Dr. Berns succeeds Dr. Marie-Louise Fjällskog, who is stepping down from her current CMO role at Faron.
  • “I am delighted to welcome Birge to Faron as the interim Chief Medical Officer as we progress our ambitious clinical development program for bexmarilimab," said Dr. Markku Jalkanen, Chief Executive Officer of Faron.

Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development

Retrieved on: 
Wednesday, September 13, 2023
King's Cross, Faculty, Drug development, University, NMT, Cancer research, Hook effect, Drug, Emergent, MBA, Faculty of Pharmaceutical Medicine, Novartis, Daiichi Sankyo, ESCP Business School, ADC, Spacecraft, IND, Pharmaceutical medicine, Pharmaceutical industry, Fine chemical, Chiron

LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.

Key Points: 
  • LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
  • In this new role, Dr. McLeod joins the Leadership Team and will be responsible for developing the clinical strategy and IND submissions as the company advances its targeted ADC pipeline towards clinical trials.
  • Welcoming Robert to the company, Myricx CEO Dr. Robin Carr said: “We are very pleased to have attracted Robert to the company.
  • In addition, in line with its strategy to focus on the development of NMT inhibitors as novel cytotoxic payloads for ADCs, the Company has recently rebranded from Myricx Pharma to Myricx Bio.

MAPLIGHT THERAPEUTICS APPOINTS TIM GARNETT, M.D. TO BOARD OF DIRECTORS

Retrieved on: 
Monday, July 24, 2023
Faculty, Fraud Advisory Panel, Bachelor, Endocrinology, Royal college, MapLight, Drug development, MBBS, University of London, Therapy, University, FRCOG, MBA, Faculty of Pharmaceutical Medicine, Eli Lilly, DSM-IV codes, Neuroscience, Lilly, MD, SAN, Entrepreneurship, FFPM, Pharmaceutical medicine, Pharmaceutical industry, Management, Medicine

SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D. to its Board of Directors. Dr. Garnett is a pharmaceutical executive with decades of experience in drug development and strategic portfolio management.

Key Points: 
  • SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D.
  • Dr Garnett has served on multiple boards and is currently Board Chair of Ophirex, a Board Member of Carmot Therapeutics and a member of the Advisory Panel of Cambridge Innovation Capital.
  • "I am proud to join MapLight's Board of Directors as the company moves multiple drug candidates through development and on to registrational trials," said Tim Garnett, MD.
  • "MapLight has a promising pipeline of novel assets and a talented leadership team of distinguished neuroscience veterans unique within biopharma.

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Retrieved on: 
Wednesday, June 28, 2023
Emergency Use Authorization, Faculty, University College London, GSK plc, Drug development, Therapy, Quality of life, Faculty of Pharmaceutical Medicine, CMO, Dermatology, MD, Patient, Cardiology, FDA, Pharmaceutical medicine, Pfizer, Pharmaceutical industry, Teva

JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.

Key Points: 
  • JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.
  • Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affairs and overseeing the launch of new drugs across multiple geographies.
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “We are excited to welcome Camilla to our team.
  • She joins InflaRx from Kyowa Kirin Corporation, where she was Vice President & Global Medical Affairs Therapy Area Head - Immunology.